Extracorporeal shock wave therapy for the treatment of ganglions of the hand

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038791

Enrollment

Registered

2025-12-22

Start date

2026-01-19

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ganglion cyst on the extensor side of the wrist

Interventions

Group 1: Intervention group: -Sonographic examination of the ganglion, completion of questionnaires (DASH

SF-12 and our own questionnaire on pain symptoms, other therapies, and ability to work) -first shock wave appointment, 15 min: ESWT treatment (week 1) -Second shock wave appointment, 15 min: ESWT trea

SF-12 and our own questionnaire on pain symptoms, further therapies, and ability to work) -Follow-up appointment after 12 weeks, repeat sonographic examination of the ganglion, completion of questionn

SF-12 and our own questionnaire on pain symptoms, further therapies, and ability to work)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Sonographic evidence of a ganglion on the extensor side of the wrist • Written patient consent to participate in the study (informed consent)

Exclusion criteria

Exclusion criteria: • Previous ESWT on the affected hand within the last 12 months • Malignant tumor processes in the treatment area • Skin defects in the treatment area • Severe psychiatric illness • Legal guardianship in medical matters by third parties

Design outcomes

Primary

Measure	Time frame
Difference in the size of the ganglion of the extensor side of the wrist (sonographic) before the start of therapy and after the end of therapy	—

Secondary

Measure	Time frame
•Difference in hand function level (DASH assessment) after the end of therapy and before the start of therapy •Change in quality of life: physical and mental (SF-12) after the end of therapy and before the start of therapy •Change in pain symptoms: duration and type after the end of therapy and before the start of therapy (own questionnaire) •Change in the need for further measures (including medication) due to pain symptoms after the end of therapy and before the start of therapy (own questionnaire) •Change in ability to work after the end of therapy and before the start of therapy (own questionnaire)	—

Measure

Time frame

•Difference in hand function level (DASH assessment) after the end of therapy and before the start of therapy •Change in quality of life: physical and mental (SF-12) after the end of therapy and before the start of therapy •Change in pain symptoms: duration and type after the end of therapy and before the start of therapy (own questionnaire) •Change in the need for further measures (including medication) due to pain symptoms after the end of therapy and before the start of therapy (own questionnaire) •Change in ability to work after the end of therapy and before the start of therapy (own questionnaire)

—

Countries

Germany

Contacts

Public ContactChristina Lemhöfer

Universitätsklinikum Jena

christina.lemhoefer@med.uni-jena.de03641 93252-01

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026